Interestingly, it has been shown that treatment with PACAP decreased AD pathology by stimulating the nonamyloidogenic processing of amyloid precursor protein and increased the expression of neuroprotective factors [53,54]. This evidence concerns the gene ADCYAP1 and Alzheimer disease.